ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025
Communications Among Neurocytes in Parkinson's Disease Regulated by Differential Metabolism and Blood-Brain Barrier Traversing of Chiral Gold Cluster-MOF Integrated Nanoparticles.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Single-Cell Profiling Reveals Clonally Expanded CX3CR1Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Metal-Organic Framework Nanozymes: From Rational Design and Synthesis to Biomedical Applications.Nano-micro letters · 2026Review
- Chemokine Networks in Blood-Brain Barrier Regulation: Bidirectional Mechanisms, Clinical Translation, and Precision Therapeutic Prospects.Biomolecules · 2026Review
- Atomically Precise Clusterzymes: A Programmable Optoelectronic Platform for Neuroscience.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Exosomes Regulate the NLRP3/Caspase-1/IL-1β Signaling Pathway in Parkinson's Disease: Mechanisms of Neuroinflammation Modulation and α-Synuclein Propagation.Neuropsychiatric disease and treatment · 2026Review
- Research progress on mRNA drug delivery strategies in the nervous system.Nanomedicine (London, England) · 2025Review
- Communications Among Neurocytes in Parkinson's Disease Regulated by Differential Metabolism and Blood-Brain Barrier Traversing of Chiral Gold Cluster-MOF Integrated Nanoparticles.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
This study have previously reported that ZIF-based chiral nanomedicines achieve Parkinson's disease (PD) therapy through differential metabolism and relief of neuroinflammation. However, lack of overall chirality and anti-inflammatory capacity of nanomedicines limit the further effective solution to the nanobiological effects research in PD. Here, it dexterously loaded chiral gold nanoclusters (AuNCs) onto the inner and outer surfaces of ZIF to achieve the purpose of simultaneously improving the overall chirality and anti-inflammatory activity of the composite nanoparticles (NPs). There are significant differences in the composition of protein corona between different chiral NPs, which elucidates the mechanism of chiral-mediated discrepancies in metabolism and the blood-brain barrier (BBB) traversing. Multi-omics and biochemical techniques further reveal that chiral NPs interfere with the chemokine axis (CX3CL1/CX3CR1)-NF-κB-NLRP3 and PI3K-AKT signaling pathways, regulate communications between neurons, neural stem cells and microglia ("the three-body problem"), and induce anti-inflammatory efficacy of microglia mitochondrial energy metabolic reprogramming in PD. The research uncovers the biodistribution, metabolic variances, and therapeutic mechanism of chiral NPs, providing deep insights into the nanobiological effects of chiral anti-inflammatory nanomedicines in PD therapy for future clinical transformation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.